Clinical Trial Update: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant modified FOLFIRINOX with stereotactic body radiation therapy in borderline resectable pancreatic adenocarcinoma; study termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Modified FOLFIRINOX (modified FOLFIRINOX)
• Stereotactic Body Radiation Therapy (SBRT)

Snippet

Sponsor: Yale University | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-10-27